Metaproterenol

Class
Bronchodilators
Subclass
Short-acting beta-agonists
Substance name
Metaproterenol
Common formulations
Syrup
Dosage and administration
Adults patients
Reversible airway obstruction in patients with asthma
20 mg PO q6-8h
Reversible airway obstruction in patients with COPD
20 mg PO q6-8h
Indications for use
Labeled indications
Adults
Symptomatic relief of reversible airway obstruction in patients with asthma
Symptomatic relief of reversible airway obstruction in patients with COPD
Safety risks
Boxed warnings
Cardiac arrhythmias
Use extreme caution with cardiovascular disorders.
Serotonin syndrome
Use extreme caution with concomitant MAOI therapy.
Contraindications
A seizure disorder
Diabetes mellitus
Thyroid disease
Specific populations
Renal impairment
eGFR 0-90 mL/min/1.73 m²
Use acceptable. No dose adjustment required.
Renal replacement therapy
Any modality
Use acceptable. No dose adjustment required.
Hepatic impairment
Any severity
Use acceptable. No dose adjustment required.
Pregnancy and breastfeeding
Pregnancy
All trimesters
Use only if benefits outweigh potential risks. Evidence of fetal harm in animals.
Breastfeeding
Acceptable for use during breastfeeding.
NOT MARKETED IN THE US.
Unknown amount excreted in breastmilk.
Unknown drug levels in breastfed infants.
Adverse reactions
Very common > 10%
Tachycardia, tremor
Common 1-10%
Dizziness, fatigue, headache, nausea, palpitations
Uncommon < 1%
Diaphoresis, hypertension, myoclonus, blurred vision, chills, cough, dry mouth, dysgeusia, fever, generalized pruritus, muscle cramps, musculoskeletal pain, somnolence, syncope, vomiting
Unknown frequency
Abdominal distension, bronchospasm, ↓ serum potassium, exacerbation of arrhythmia, premature ventricular contractions, ↑QTc interval, hallucinations, insomnia, nervousness, paranoid ideation, shaking, skin flushing, stupor
Interactions
Drug(s)
Check Interactions
Reset

What did you think about this content?

Create free account

Sign up for free to access the full drug resource